- Conditions
- Nonfluent Aphasia, Stroke
- Interventions
- levodopa/carbidopa, Placebo comparator
- Drug
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 253
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
- Interventions
- 240mg Amantadine HCl ER tablets, Placebo tablets, 320mg Amantadine HCl ER tablets
- Drug
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Sinemet, IPX203
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Boca Raton, Florida • Naples, Florida + 7 more
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Interventions
- ADS-5102, Placebo
- Drug · Other
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 21
- States / cities
- Fountain Valley, California • Sunnyvale, California • Boca Raton, Florida + 18 more
- Conditions
- Parkinson's Disease
- Interventions
- ND0612
- Drug
- Lead sponsor
- NeuroDerm Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 23 more
- Conditions
- Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
- Interventions
- amantadine HCl ER, Placebo
- Drug
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- XADAGO (safinamide)
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 30
- States / cities
- Homewood, Alabama • Bakersfield, California • Laguna Hills, California + 27 more
- Conditions
- Parkinson's Disease
- Interventions
- KW-6002 (istradefylline)
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Parkinson Disease
- Interventions
- Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Disorder of Consciousness, Traumatic Brain Injury
- Interventions
- Amantadine + L-DOPA, NMDA blocker
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Parkinson Disease
- Interventions
- CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Congenital Hyperinsulinism
- Interventions
- 18F-Fluoro Dopa Imaging
- Drug
- Lead sponsor
- Miguel Pampaloni
- Other
- Eligibility
- 0 Days to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Parkinson's Disease, Motor Fluctuations
- Interventions
- DM-1992, Sinemet IR
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 4 more
- Conditions
- Freezing of Gait Symptoms in Parkinson Disease
- Interventions
- Active Stimulation, Sham (No Treatment)
- Device
- Lead sponsor
- Iahn Cajigas
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Chronic Pain
- Interventions
- Methylphenidate, carbidopa-levodopa, Placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Parkinson Disease
- Interventions
- Postural perturbation
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Salt Lake City, Utah
- Conditions
- Parkinson Disease
- Interventions
- Lenrispodun, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 31 more
- Conditions
- Parkinson's Disease
- Interventions
- rasagiline mesylate, rasagiline mesylate 1.0 mg
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 7
- States / cities
- Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Parkinson Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson's Disease
- Interventions
- IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, IPX066 245 mg
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Parkinson's Disease, Dyskinesias
- Interventions
- Intravenous Levodopa, ACP-103
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease
- Interventions
- Opicapone, Carbidopa Levodopa
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Glendale, California • Long Beach, California • Farmington Hills, Michigan
- Conditions
- Parkinson's Disease
- Interventions
- Istradefylline (KW-6002)
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Stress Disorder, Post Traumatic
- Interventions
- Placebo, Levodopa
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas